Last reviewed · How we verify
Praziquantel and Albendazole
At a glance
| Generic name | Praziquantel and Albendazole |
|---|---|
| Also known as | DISTOCIDE, ZENTEL |
| Sponsor | Catholic University of Health and Allied Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel (PHASE4)
- HIV And Parasitic Infection (HAPI) Study (NA)
- Oxfendazole in Mild Parenchymal Brain Cysticercosis (PHASE2, PHASE3)
- Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis (PHASE4)
- Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control (NA)
- Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) (PHASE3)
- Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children (NA)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: